Abiopharma

🔍 Onyia Jude (Executive)

Company: NEUROCRINE BIOSCIENCES INC (NBIX)

Report Date: 2026-06-01

Detailed Transactions and Holdings:

• Acquired 11,000 shares of Common Stock at $84.74 per share (Direct)
  Date: 2026-06-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 36,846.00 | transaction_form_type: 4
• Sold 11,000 shares of Common Stock at $160.2464 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 25,846.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 11,000 shares of Non-Qualified Stock Option at $84.74 per share (Derivative)
  Date: 2026-06-01 | Code: M | Expires: 2031-11-29 | equity_swap_involved: 0 | shares_owned_after: 13,268.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
• F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F3: Represents option of which 1/4th of the shares underlying the option became vested and exercisable on November 29, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.